Johnson & Johnson News
Can Bristol-Myers Squibb keep its amazing growth in 2013 going strong in the future? It'll rely on ballyhooed drugs like these to discover its future growth.
The approval of Gilead's Sovaldi sets the drug up to compete with Johnson & Johnson's Olysio, leaving Vertex Pharmaceuticals' and Merck's first-generation hepatitis C drugs in their wake. The fight may be short-lived, though, as patients wait for all-oral combinations from Gilead and AbbVie.
Hospira provided an insight regarding its way forward at its Investor Day
A look at what may be lying ahead in 2014 for Johnson & Johnson and its shareholders.
Gilead Potential Blockbuster Hep C Drug Wins FDA Nod
2 Top Biotechs Presenting Data At Hematology Event
Top 10 Equity Analyst Interviews of 2013: Significant Stock Price Appreciation and Increased M&A from Biotech Productivity and InnovationWall Street Transcript Dec 6
67 WALL STREET, New York - December 6, 2013 - The Wall Street Transcript has just published its Top Ten Equity Analyst Interviews 2013 Report. This special feature contains expert industry commentary through ...
Johnson & Johnson was a winner within the drugs industry, rising $1.47 (1.6%) to $94.44 on average volume
This morning, Credit Suisse increased its price target on shares of Johnson & Johnson (JNJ) to $94 as growth from Invokana is expected to be better than originally expected. In the report, Credit Suisse maintained its underperform rating on the stock. Shares of Johnson & Johnson were higher on Friday, [...]
Here are four more themes where you can put money to work.
With Gilead (GILD), Johnson and Johnson (JNJ), AbbVie (ABBV), Bristol-Myers (BMY), and Merck (MRK) rushing to get next generation hepatitis C drugs to market, here are the facts you need to see.
TheStreet highlights 5 stocks pushing the health care sector higher today.
Here are a whole new crop of stocks that I think can beat next year's market.
From the very first article I wrote on retirement portfolio management, I have suggested that investors seeking income buy on the dips when the opportunity arises. With the development of our 2 Team Alpha ...
Looking for dependable dividends with a long history of growth? Consider Procter & Gamble and Johnson & Johnson.